logo

For the Inventor, By the Inventor

Yeoju, South Korea

Ji Sook Kim

This inventor holds 12 USPTO granted patents and 1 published patent application and 4 EPO patents. Top assignees: Hanmi Pharm. Co., Ltd., Hanmi Holdings Co., Ltd., Hanmi Pharmaceutical Co., Ltd.. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ji Sook Kim. Retrieved from https://idiyas.com/inventor/ji-sook-kim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 12 

% Patents Active = 66.7

 

Average Co-Inventor Count = 6.6

ph-index = 2

Forward Citations = 7(Granted Patents)


Location History:

  • Gyeonggi-do, KR (2012 - 2014)
  • Yeoju-gun, KR (2012 - 2014)
  • Yongin-si, KR (2017)
  • Hwaseong-si, KR (2020 - 2022)

Company Filing History:

goldMedal8 out of 148 
 
Hanmi Pharm. Co., Ltd.
 patents
silverMedal1 out of 12 
 
Hanmi Holdings Co., Ltd.
 patents
bronzeMedal1 out of 8 
 
Hanmi Pharmaceutical Co., Ltd.
 patents
4. 1 out of 1 
 
Hanmi Science
 patent
5. 1 out of 63 
 
Hanmi Science Co., Ltd.
 patents

Years Active: 2012-2025

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 12479845 - Imidazopyridine derivative compounds and use of same (2025-11-25),
2. 12433867 - Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia (2025-10-07),
3. 12325698 - Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same (2025-06-10),
4. 11292786 - Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same (2022-04-05),
5. 11254676 - Pyrazole derivative compound and use thereof (2022-02-22),
6. 10870639 - Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same (2020-12-22),
7. 10696675 - Imidazopyridopyrimidine derivative compound and use thereof (2020-06-30),
8. 9828366 - Bicyclic derivatives and pharmaceutical composition including the same (2017-11-28),
9. 8853213 - Bicyclic compound for modulating G protein-coupled receptors (2014-10-07),
10. 8637700 - Method for preparing (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone and novel intermediate used therefor (2014-01-28),
11. 8263769 - Process for preparing voriconazole (2012-09-11),
12. 8242288 - Method of preparing (6R)-3-hexyl-4-hydroxy-6-undecyl-5, 6-dihydropyran-2-one, and intermediate used in the method (2012-08-14),

Title: Ji Sook Kim: Innovator in Pharmaceutical Composition

Introduction

Ji Sook Kim is a prominent inventor based in Yeoju-gun, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of acute myeloid leukemia and various cancers. With a total of 12 patents to his name, his work continues to impact the medical community.

Latest Patents

Among his latest patents is a pharmaceutical composition comprising a FLT3 inhibitor and a hypomethylating agent for treating acute myeloid leukemia. This innovative composition is designed to provide a therapeutically effective combination for patients suffering from AML. Another notable patent involves pyrimidine compounds and pharmaceutical compositions aimed at preventing or treating cancers, showcasing his commitment to advancing cancer treatment.

Career Highlights

Ji Sook Kim has worked with reputable companies such as Hanmi Pharm. Co., Ltd. and Hanmi Science. His experience in these organizations has allowed him to develop groundbreaking pharmaceutical solutions that address critical health issues.

Collaborations

Throughout his career, Ji Sook Kim has collaborated with esteemed colleagues, including Young Gil Ahn and In Hwan Bae. These partnerships have fostered an environment of innovation and creativity in the pharmaceutical field.

Conclusion

Ji Sook Kim's contributions to pharmaceutical innovation are noteworthy and continue to influence the treatment of serious health conditions. His dedication to research and development exemplifies the spirit of innovation in the medical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…